These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 9699325)
1. Ovarian activity before and after gonadal suppression by GnRH-a in patients with polycystic ovary syndrome, hyperandrogenism, hyperinsulinism and acanthosis nigricans. Motta EL; Baracat EC; Haidar MA; Juliano I; Lima GR Rev Assoc Med Bras (1992); 1998; 44(2):94-8. PubMed ID: 9699325 [TBL] [Abstract][Full Text] [Related]
2. Acromegaly with polycystic ovaries, hyperandrogenism, hirsutism, insulin resistance and acanthosis nigricans: a case report. Unal A; Sahin Y; Keleştimur F Endocr J; 1993 Apr; 40(2):207-11. PubMed ID: 7951506 [TBL] [Abstract][Full Text] [Related]
3. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. Dunaif A; Mandeli J; Fluhr H; Dobrjansky A J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783 [TBL] [Abstract][Full Text] [Related]
4. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986 [TBL] [Abstract][Full Text] [Related]
5. Role of obesity and hyperinsulinemia in the insulin resistance of obese subjects with the clinical triad of polycystic ovaries, hirsutism and acanthosis nigricans. Wajchenberg BL; Giannella-Neto D; Lerario AC; Marcondes JA; Ohnuma LY Horm Res; 1988; 29(1):7-13. PubMed ID: 3397043 [TBL] [Abstract][Full Text] [Related]
6. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. Dunaif A; Graf M; Mandeli J; Laumas V; Dobrjansky A J Clin Endocrinol Metab; 1987 Sep; 65(3):499-507. PubMed ID: 3305551 [TBL] [Abstract][Full Text] [Related]
7. A syndrome of hyperandrogenism, insulin resistance, and acanthosis nigricans associated with polycystic ovary syndrome: clinical and laboratory features. Taketani Y; Mizuno M Horm Res; 1990; 33 Suppl 2():27-30. PubMed ID: 2095357 [TBL] [Abstract][Full Text] [Related]
8. Growth hormone and somatomedin-C secretion in patients with polycystic ovarian disease. Their relationships with hyperinsulinism and hyperandrogenism. Lanzone A; Fulghesu AM; Pappalardo S; Proto C; Le Donne M; Andreani CL; Muscatello R; Caruso A; Mancuso S Gynecol Obstet Invest; 1990; 29(2):149-53. PubMed ID: 2110544 [TBL] [Abstract][Full Text] [Related]
9. Impaired insulin degradation in a patient with insulin resistance and acanthosis nigricans. Ferrannini E; Muggeo M; Navalesi R; Pilo A Am J Med; 1982 Jul; 73(1):148-54. PubMed ID: 7046438 [TBL] [Abstract][Full Text] [Related]
10. Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. Dunaif A; Hoffman AR; Scully RE; Flier JS; Longcope C; Levy LJ; Crowley WF Obstet Gynecol; 1985 Oct; 66(4):545-52. PubMed ID: 3900841 [TBL] [Abstract][Full Text] [Related]
11. [Woman 19-old with hirsutism, obesity and acanthosis nigricans]. Kępczyńska-Nyk A; Muszel M; Radziszewski M; Wocial K Pol Merkur Lekarski; 2016 Sep; 41(243):141-144. PubMed ID: 27755516 [TBL] [Abstract][Full Text] [Related]
12. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. White D; Leigh A; Wilson C; Donaldson A; Franks S Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565 [TBL] [Abstract][Full Text] [Related]
14. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion. Allon MA; Leach RE; Dunbar J; Diamond MP Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308 [TBL] [Abstract][Full Text] [Related]
15. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone. Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389 [TBL] [Abstract][Full Text] [Related]
16. Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction. Filicori M; Flamigni C; Cognigni G; Dellai P; Michelacci L; Arnone R Fertil Steril; 1994 Aug; 62(2):279-85. PubMed ID: 8034073 [TBL] [Abstract][Full Text] [Related]
17. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome]. Li X; Lin JF Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817 [TBL] [Abstract][Full Text] [Related]
18. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents. Li L; Chen X; He Z; Zhao X; Huang L; Yang D J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573 [TBL] [Abstract][Full Text] [Related]
19. Spectrum of endocrine abnormalities associated with acanthosis nigricans. Matsuoka LY; Wortsman J; Gavin JR; Goldman J Am J Med; 1987 Oct; 83(4):719-25. PubMed ID: 3674058 [TBL] [Abstract][Full Text] [Related]